A study investigating the safety and efficacy of intranasal betahistine in patients suffering from vertigo (giddiness) after either the removal of a tumour of the balance and hearing nerve; or where a portion, or all of the inner ear is removed; or where the nerve connecting the inner ear with the brain is cut. : Multicenter randomized controlled phase 2 trial to evaluate AM-125 in thetreatment of acute peripheral vertigo following neurosurgery (TRAVERS) - AM-125 in the treatment of acute peripheral vertigo (TRAVERS)
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
WHO International Clinical Trials Registry Platform - (2019) vom: 16. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-05-2019, Last updated: 2022-11-24 |
|---|
| ICTRP ID: |
EUCTR2018-002474-52-GB |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CTG004267168 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG004267168 | ||
| 003 | DE-627 | ||
| 005 | 20230425164843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210507s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG004267168 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)EUCTR2018-002474-52-GB | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)AM-125-CL-18-01 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)NCT03908567 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)2018-002474-52-CZ | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A study investigating the safety and efficacy of intranasal betahistine in patients suffering from vertigo (giddiness) after either the removal of a tumour of the balance and hearing nerve; or where a portion, or all of the inner ear is removed; or where the nerve connecting the inner ear with the brain is cut. |b Multicenter randomized controlled phase 2 trial to evaluate AM-125 in thetreatment of acute peripheral vertigo following neurosurgery (TRAVERS) - AM-125 in the treatment of acute peripheral vertigo (TRAVERS) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-05-2019, Last updated: 2022-11-24 | ||
| 650 | 4 | |a Medical Condition: Acute peripheral vertigo MedDRA version: 20.0Level: LLTClassification code 10059614Term: Vestibular vertigoSystem Organ Class: 100000004854;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a Recruitment Status: Authorised-recruitment may be ongoing or finished | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2019) vom: 16. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:16 |g month:12 |
| 856 | 4 | 0 | |u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002474-52 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2019 |b 16 |c 12 | ||